Glioblastoma Multiforme Market By Drug Type (Bevacizumab, Temozolomide, Carmustine) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

This report on global glioblastoma multiforme market studies various drugs used for treatment of glioblastoma along with pipeline analysis of upcoming potential drugs.  Glioblastoma multiforme is the most common and most aggressive cancer that begins within the brain. According to Brain Tumour Foundation of Canada, The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours.

For the purpose of this study, the various drugs studied include bevacizumab, temozolomide, and carmustine. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for glioblastoma multiforme market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain, Rindopepimut (CDX-110), and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global glioblastoma multiforme market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Glioblastoma Multiforme Market

 


 

According to American Association of Neurological Surgeons (AANS), The National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that in 2015, 15,320 of these diagnoses resulted in death. Glioblastoma multiforme (GBM) has an incidence of two to three per 100,000 adults per year, and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic). It is categorized as one of the orphan diseases with high mortality rate.

Based on the type of drugs, the glioblastoma multiforme market is segmented into:

  • Temozolomide
  • Bevacizumab
  • Carmustine

Glioblastoma Multiforme Market

In base year 2015, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and less adverse effects compared to other molecules. Medical practitioners suggest that, combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most patients suffering from GBM. Temozolomide belongs to the class of alkylating agents; the mechanism of action comprises cell destruction initiated by abnormal methylations of DNA bases, and in particular the formation of O6-alkylguanine in DNA. The DNA repair enzyme -methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents and MGMT gene silencing through promoter methylation is a favorable prognostic marker, predicting benefits from this sort of chemotherapy in GBM. Thus, temozolomide is the first line therapy used for GBM treatment but ongoing research to enhance efficiency of bevacizumab in GBM treatment might affect the temozolomide market share in the near future.

For the purpose of this study, the global glioblastoma multiforme market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Glioblastoma Multiforme Market

In base year 2015, North America and Europe dominated the market with around 60% of the overall market share. The key factors assisting the growth of glioblastoma multiforme market in these regions are mounting support from government and non-government organizations to increase public awareness related to diagnosis and treatment of GBM and advanced healthcare infrastructure to boost the pipeline research in this market. Market experts suggest that, key GBM treatment drugs are initially approved in these regions as North American and European markets are the most lucrative pharmaceutical markets. The upcoming pipeline drugs are expected to play crucial role in the GBM market where early market entry and high drug prices would be the key factors that will boost the overall GBM market in North America and Europe initially. Asia-Pacific is expected to grow at a significant pace where Japan is observed as the leading market followed by China and India. India and China have a large low- and middle-income population; hence, demand for low cost treatments is high. However, in case of life threatening diseases such as GBM the scenario is different as the available treatments are limited and require higher cost.

Choose License Type
Published Date:  Jun 2016
Category:  Pharmaceuticals
Report ID:   57903
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Connect With Us
+1-408-641-3282
24/7 Research Support